Celebrating our 5-year anniversary, serving millions of people globally
January 16, 2022 | News
Today, five years ago, AJ Vaccines emerged as a new life science company, and thus the first steps were taken towards securing a world free of serious diseases.
It has been five eventful years where we as a company have worked purposefully and committed to develop innovative vaccines, diagnostics and therapeutic solutions of the highest quality for the world.
“It has certainly not been five years without challenges. We have had many of them, but I note that even with the last two years in the shadow of COVID-19, we have managed to continuously develop our business, competencies and culture. Compared to our first year in business, we have increased tenfold the number of vaccines delivered annually and all our solutions combined have safeguarded millions of people in more than 90 countries worldwide. This has only been possible through the continued commitment of our investors, the dedicated contributions from our highly skilled employees and through our strong partnerships with WHO and UN agencies”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
A key contributor to The Global Polio Eradication Initiative
Since the beginning in 2017, AJ Vaccines has continuously expanded and pursued new business opportunities globally. Today, AJ Vaccines holds 134 marketing authorisations globally as well as 15 ongoing applications for vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio.
In addition, we have invested significantly in the strategic expansion of our production facilities and recruitment of new employees to secure AJ Vaccines’ position as a significant player in the vaccine market.
“AJ Vaccines has established a new fully GAP III compliant polio facility. With the investments in our polio facilities, we have, among other things, been able to develop a new dose sparing polio vaccine fully supported by Bill & Melinda Gates Foundation. With this, AJ Vaccines is today positioned as a major contributor to the Global Polio Eradication Initiative (GPEI)”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
Supporting the struggle against tuberculosis
Since 2017, AJ Vaccines has re-established Western Europe’s only BCG Vaccine production to protect against tuberculosis. There is an unmet demand for vaccines globally, and tuberculosis is unfortunately still impacting millions of lives globally, which is why we are dedicated to supply and support the fight against the global killer. In addition, we also have supplied BCG vaccine to clinical studies in Denmark (SDU), Netherlands and Australia investigating the potential disease modifying immune effects of BCG administration on COVID-19 disease in Health Care Workers.
“I look forward to continue the journey of AJ Vaccines. We are committed to expand our work globally with partners and healthcare professionals, and exploring new opportunities and partnerships, to create a world free of serious diseases across generations”, concludes Jesper Helmuth Larsen, CEO AJ Vaccines.